These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 7533459)

  • 41. The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer.
    Zagars GK; Pollack A
    Cancer; 1993 Aug; 72(3):832-42. PubMed ID: 7687516
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?
    Keyser D; Kupelian PA; Zippe CD; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):723-9. PubMed ID: 9240638
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis.
    Lee WR; Hanks GE; Schultheiss TE; Corn BW; Hunt MA
    J Clin Oncol; 1995 Feb; 13(2):464-9. PubMed ID: 7531222
    [TBL] [Abstract][Full Text] [Related]  

  • 44. External beam radiotherapy dose response of prostate cancer.
    Pollack A; Zagars GK
    Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1011-8. PubMed ID: 9392538
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate.
    Zietman AL; Tibbs MK; Dallow KC; Smith CT; Althausen AF; Zlotecki RA; Shipley WU
    Radiother Oncol; 1996 Aug; 40(2):159-62. PubMed ID: 8884970
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biochemical disease-free survival following 125I prostate implantation.
    Beyer DC; Priestley JB
    Int J Radiat Oncol Biol Phys; 1997 Feb; 37(3):559-63. PubMed ID: 9112453
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era.
    Kuban DA; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Zietman AL
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):915-28. PubMed ID: 14575822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy.
    Zagars GK; Geara FB; Pollack A; von Eschenbach AC
    Cancer; 1994 Apr; 73(7):1904-12. PubMed ID: 7511040
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy.
    Pollack A; Lankford S; Zagars GK; Babaian RJ
    Cancer; 1996 Apr; 77(8):1515-23. PubMed ID: 8608537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Near-diploidy: a new prognostic factor for clinically localized prostate cancer treated with external beam radiation therapy.
    Pollack A; Zagars GK; el-Naggar AK; Gauwitz MD; Terry NH
    Cancer; 1994 Apr; 73(7):1895-903. PubMed ID: 7511039
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy.
    Zagars GK
    Int J Radiat Oncol Biol Phys; 1992; 23(1):47-53. PubMed ID: 1374065
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer.
    Zagars GK; Pollack A
    Radiother Oncol; 1997 Sep; 44(3):213-21. PubMed ID: 9380819
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The prognostic value of PSA levels in radiation therapy of patients with carcinoma of the prostate: the UCLA experience 1988-1992.
    Schneider SB; Schweitzer VG; Parker RG; Bycott PW
    Am J Clin Oncol; 1996 Feb; 19(1):65-72. PubMed ID: 8554039
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Do the results of systematic biopsies predict outcome in patients with T1-T2 prostate cancer treated with radiation therapy alone?
    Lee WR; Hanlon A; Hanks GE
    Urology; 1996 May; 47(5):704-7. PubMed ID: 8650869
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.
    Shipley WU; Thames HD; Sandler HM; Hanks GE; Zietman AL; Perez CA; Kuban DA; Hancock SL; Smith CD
    JAMA; 1999 May; 281(17):1598-604. PubMed ID: 10235152
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer.
    Beyer DC; Thomas T; Hilbe J; Swenson V
    Brachytherapy; 2003; 2(2):77-84. PubMed ID: 15062144
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prostate-specific antigen cancer volume: a significant prognostic factor in prostate cancer patients at intermediate risk of failing radiotherapy.
    Lankford SP; Pollack A; Zagars GK
    Int J Radiat Oncol Biol Phys; 1997 May; 38(2):327-33. PubMed ID: 9226319
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The results of radical prostatectomy at a community hospital during the prostate specific antigen era.
    Smitt MC; Heltzel M
    Cancer; 1996 Mar; 77(5):928-33. PubMed ID: 8608486
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is prostate specific antigen density an important prognostic indicator for patients with prostate cancer treated with external beam therapy?
    Aref I; Eapen L; Agboola O; Cross P
    Br J Radiol; 1998 Aug; 71(848):868-71. PubMed ID: 9828800
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy.
    Lee WR; Hanks GE; Corn BW; Schultheiss TE
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):21-4. PubMed ID: 7527798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.